An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

Speciality: Oncology


Speaker:

Dr. Bhavna Parikh | Senior Consultant Medical Oncologist, Bombay Hospital & Medical Research Centre, Lilavati Hospital, Hinduja Hospital Khar and Bharatiya Arogya Nidhi Hospital

Description:

A warm welcome to all the medical professionals joining us for this insightful session on the multifaceted advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies. The landscape of advanced breast cancer treatment has been profoundly reshaped by the advent of CDK4/6 inhibitors. These targeted therapies, including palbociclib, ribociclib, and abemaciclib, have revolutionized the management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, demonstrating significant improvements in progression-free and overall survival rates compared to traditional endocrine therapy alone. Their mechanism of action, by selectively inhibiting cyclin-dependent kinases 4 and 6, effectively halts cell cycle progression and offers a more precise approach to combating cancer.

Dr. Bhavna Parikh, a distinguished expert in the field, will delve into the compelling clinical evidence supporting the widespread adoption of these agents. Through landmark clinical trials, CDK4/6 inhibitors have consistently shown superior efficacy, extending the time patients live without disease progression and enhancing their quality of life. This session will explore the nuances of these studies, highlighting the patient populations who benefit most, the optimal sequencing strategies, and the management of potential side effects, ensuring a comprehensive understanding of their practical application in clinical settings.

The integration of CDK4/6 inhibitors into the treatment paradigm for HR+/HER2- advanced breast cancer represents a monumental leap forward in personalized oncology. This webinar is an invaluable opportunity to gain an overall knowledge of the best practices and latest advancements in leveraging these inhibitors for improved patient outcomes. Don't miss this chance to grab the shared knowledge and follow Hidoc for more such interesting webinar sessions that keep you at the forefront of medical innovation.

See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

2.

Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.

3.

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients

4.

A large study found that monolayers were superior in detecting cancer.

5.

New drug combination shows particularly good results in patients with HPV-negative head and neck cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot